This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Indian pharma manufacturing continues to be the backbone of drug supplies worldwide, and GlobalData analysis suggests US overreliance on the country for genericdrug supply. US reliance on India for genericdrugs could have supply chain security and quality implications for critical medicines.
The therapeutic candidate targets immune checkpoint, programmed cell death protein 1 (PD1). The company also provides genericdrugs and contract development and manufacturing services across its global network. It is administered as an intravenous infusion. It is developed based on sympress platform technology.
The French group said that ORI-001, a vaccine based on recombinant proteins from the Cutibacterium acnes (formerly Propionibacterium acnes ) bacterium that is often found in acne lesions, could be the first ever vaccine for the condition. C acnes is implicated in moderate to severe acne, which is difficult to treat.
To demonstrate bioequivalence for a generic small molecule drug, a company must carry out a Phase I clinical trial in healthy individuals to ensure that the area under the curve and maximum plasma concentration for their drug is equivalent to that of the brand name drug.
In order to fact-check some of these misconceptions, the US Food and Drug Administration (FDA) recently hosted a webinar on biosimilar and interchangeable biological products to help healthcare professionals understand more about these treatment options. Biosimilars are the “generic” drugs of the biopharma world.
Here’s an overview of the differences between them: Composition and Size : Small Molecules: These are chemically synthesized drugs that are generally low in molecular weight, typically less than 900 Daltons. Biologics: Biologics are large, complex molecules, often proteins, that are produced using living cells.
Stelara’s patents are expiring in September 2023, while a handful of biosimilar drugs are in late-stage development or seeking FDA approval. The FDA approved the drug over a decade ago in September 2009. billion the druggenerated in 2021. Johnson & Johnson’s total global earnings from Stelara were $9.72
Sandostatin (Octreotide) Sandostatin 2022 sales: $1.238 billion Company/Developer: Novartis Date of first FDA approval: October 21, 1988 Indications Sandostatin is FDA-approved for: Sandostatin is a synthetic protein closely resembling the natural hormone somatostatin in the human body. million the drug made during the same time in 2022.
Sandostatin (Octreotide) Sandostatin 2022 sales: $1.238 billion Company/Developer: Novartis Date of first FDA approval: October 21, 1988 Indications Sandostatin is FDA-approved for: Sandostatin is a synthetic protein closely resembling the natural hormone somatostatin in the human body. million the drug made during the same time in 2022.
In February 2021, Pfizer and BioNTech announced results from an in vitro study published in NEJM that demonstrated sera from individuals immunized with BNT162b2 neutralize SARS-CoV-2 with the South African variant spike protein. The study investigated the full set of South African variant (also known as B.1.351
The company’s candidate vaccine, mRNA-1273, is a synthetic messenger RNA that encodes the stabilized SARS-CoV-2 spike protein. The University of Oxford/AstraZeneca partnership, in turn, is testing a viral-vectored coronavirus vaccine that again expresses the spike protein of SARS-CoV-2 virus.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content